Mesenchymal Stem Cells: Their Role in the Tumor Microenvironment

Ramírez-Arbeláez, Jaime Alberto; Múnera, Luz Marina Restrepo

doi:10.1089/ten.teb.2023.0048

Cited by 4 publications

(2 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stem cells (MSCs) can differentiate into adipocytes, osteoblasts, and chondrocytes, among other mesodermal lineages 38 . As a result of their ability to modulate the tumor microenvironment (TME), MSCs have received considerable attention in recent years [39][40][41] . It is important to note that MSCs have a dual nature when used to treat cancer.…”

Section: Cancer Stem Cells Origin and Mechanism Of Actionmentioning

confidence: 99%

In Vivo Stem Cell Discoveries: Promising Implications in Cancer Therapy

Gevargiz Sangar,

Agahi,

Azizi

et al. 2023

J Lab Anim. Res

View full text Add to dashboard Cite

The remarkable regenerative abilities and versatility of stem cells have long attracted researchers. Recently, in vivo studies have revealed exciting results related to stem cells, particularly their use in cancer treatment. This review will provide an overview of these discoveries and their broader implications for the future. There is growing in vivo evidence that stem cells have immense therapeutic potential in treating various diseases, including cancer, because of their self-renewal and differentiation capabilities. As a result of in vivo research, critical aspects of stem cell behavior within tumor microenvironments have been clarified, providing a deeper understanding of their potential therapeutic utility. Several in vivo studies have demonstrated the potential of stem cell-engineered tumor-targeting agents or therapeutic payloads for the precise delivery of medicinal drugs when these agents are engineered to express them in tumor cells. Through targeted therapies, off-target effects can be minimized, and the therapeutic index of the anti-cancer agents can be improved. Several stem cell-based delivery systems have shown remarkable efficacy in preclinical in vivo studies, including breast, lung, and pancreatic cancer, indicating their potential as a novel therapeutic strategy. Moreover, in vivo studies have revealed that the immunomodulatory properties of stem cells modulate the immune response and modify the tumor microenvironment to suppress it. In particular, using checkpoint inhibitor therapy with stem cells has paved the way for innovative immunotherapeutic strategies. Research on stem cells in vivo has also provided invaluable insights into stem cell biology and their interaction with cancer cells. Due to these findings, there is an increasing understanding of tumor initiation, progression, and resistance mechanisms, which has opened avenues for improving cancer treatment by developing more effective treatments. As a result of the in vivo studies that have taken place so far, there is a wealth of information regarding the potential of stem cells in cancer treatment. This research opens up exciting prospects for the future of oncology, from the delivery of targeted drugs to immunomodulation and improving our understanding of tumor biology.

show abstract

Section: Cancer Stem Cells Origin and Mechanism Of Actionmentioning

confidence: 99%

In Vivo Stem Cell Discoveries: Promising Implications in Cancer Therapy

Gevargiz Sangar,

Agahi,

Azizi

et al. 2023

J Lab Anim. Res

View full text Add to dashboard Cite

show abstract

“…However, existing research has failed to elucidate the specific molecular mechanisms underlying the proliferation and invasion of OS cells. Previous studies have indicated that stromal cells, including mesenchymal stem cells (MSCs), in the tumor microenvironment can influence the proliferation and invasion of cancer cells by generating a series of signaling factors [ 16 , 17 ]. Studies have successfully demonstrated that the transformation of MSCs into OS cells can occur through aneuploidy and genome loss, suggesting a potential derivation of OS cells from BMSCs [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma

Zheng,

Cheng,

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Osteosarcoma (OS) is a primary malignant bone tumor arising from mesenchymal cells. The standard clinical treatment for OS involves extensive tumor resection combined with neoadjuvant chemotherapy or radiotherapy. OS's invasiveness, lung metastasis, and drug resistance contribute to a low cure rate and poor prognosis with this treatment. Metallothionein 1G (MT1G), observed in various cancers, may serve as a potential therapeutic target for OS. Methods: OS samples in GSE33382 and TARGET datasets were selected as the test cohorts. As the external validation cohort, 13 OS tissues and 13 adjacent cancerous tissues from The Second Affiliated Hospital of Nanchang University were collected. Patients with OS were divided into high and low MT1G mRNA-expression groups; differentially expressed genes (DEGs) were identified as MT1G-related genes. The biological function of MT1G was annotated using Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) and gene set enrichment analysis (GSEA). Gene expression correlation analysis and competing endogenous RNA (ceRNA) regulatory network construction were used to determine potential biological regulatory relationships of DEGs. Survival analysis assessed the prognostic value of MT1G. Results: MT1G expression increased in OS samples and presented higher in metastatic OS compared with non-metastatic OS. Functional analyses indicated that MT1G was mainly associated with spliceosome. A ceRNA network with DEGs was constructed. MT1G is an effective biomarker predicting survival and correlated with increased recurrence rates and poorer survival. Conclusions: This research identified MT1G as a potential biomarker for OS prognosis, highlighting its potential as a therapy target.

show abstract

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics

Tang,

Chen,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC‐derived extracellular vesicles (MSCs‐EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs‐EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs‐EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs‐EVs in cancer treatment, along with the challenges they face.

show abstract

Mesenchymal Stem Cells: Their Role in the Tumor Microenvironment

Cited by 4 publications

References 104 publications

In Vivo Stem Cell Discoveries: Promising Implications in Cancer Therapy

In Vivo Stem Cell Discoveries: Promising Implications in Cancer Therapy

Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics

Contact Info

Product

Resources

About